PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Vaxcyte, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$63.68+0.06 (+0.09%)
Close on Oct 19, 2026
- Market cap
- $9.20B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Vaxcyte, Inc. cash flow statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -25.6%
Financial strength
- Current ratio
- 5.72
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 67.5%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.34
- Dividend yield
- 0.00%